PPARG and metabolic dysfunction-associated steatohepatitis: The CU06-1004-treated mice in the moderate (6-week), but not mild (3-week), NASH group exhibited significantly decreased expression of peroxisome proliferator-activated receptors γ (PPARγ) relative to the CD group (Fig 2I).